These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33429405)

  • 1. In Brief: Extended-release budesonide (Ortikos) for Crohn's disease.
    Med Lett Drugs Ther; 2020 Nov; 62(1610):176. PubMed ID: 33429405
    [No Abstract]   [Full Text] [Related]  

  • 2. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
    McKeage K; Goa KL
    Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
    Florin TH; Graffner H; Nilsson LG; Persson T
    Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
    Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
    Abreu MT
    Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
    [No Abstract]   [Full Text] [Related]  

  • 7. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
    Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
    Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
    Edsbäcker S; Andersson T
    Clin Pharmacokinet; 2004; 43(12):803-21. PubMed ID: 15355126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral budesonide approved for active Crohn's disease.
    Thompson CA
    Am J Health Syst Pharm; 2001 Dec; 58(23):2229. PubMed ID: 11763799
    [No Abstract]   [Full Text] [Related]  

  • 10. Controlled-release budesonide in Crohn's disease.
    Drug Ther Bull; 1997 Apr; 35(4):30-1. PubMed ID: 9282408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.
    Lundin PD; Edsbäcker S; Bergstrand M; Ejderhamn J; Linander H; Högberg L; Persson T; Escher JC; Lindquist B
    Aliment Pharmacol Ther; 2003 Jan; 17(1):85-92. PubMed ID: 12492736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide in the treatment of Crohn's disease: a meta-analysis.
    Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide modified-release capsules.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide for induction of remission in Crohn's disease.
    Otley A; Steinhart AH
    Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide substitution in Crohn's disease relieves CNS toxicity of systemic steroids.
    Thomas MC; Schlup MM
    Med J Aust; 1998 Nov; 169(10):560. PubMed ID: 9861918
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and effectiveness of long-term budesonide treatment in maintaining remission in patients with mild-to-moderate Crohn's disease.
    Tursi A; Giorgetti GM; Brandimarte G; Elisei W
    Inflamm Bowel Dis; 2007 Sep; 13(9):1184-6. PubMed ID: 17410564
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
    Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
    J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budesonide for Crohn's disease.
    Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy.
    Beaulieu DB; Ananthakrishnan AN; Issa M; Rosenbaum L; Skaros S; Newcomer JR; Kuhlmann RS; Otterson MF; Emmons J; Knox J; Binion DG
    Inflamm Bowel Dis; 2009 Jan; 15(1):25-8. PubMed ID: 18680195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.